About IGM Biosciences
IGM Biosciences is a company based in Mountain View (United States) founded in 2010 was acquired by Concentra Biosciences in July 2025.. IGM Biosciences has raised $102.67 million across 3 funding rounds from investors including Haldor Topsoe, Janus Henderson Investors and Redmile Group. The company has 181 employees as of December 31, 2022. IGM Biosciences offers products and services including IgM Antibodies and Antibody Platform. IGM Biosciences operates in a competitive market with competitors including Moderna, Horizon Therapeutics, Forge Biologics, Dren Bio and argenx, among others.
- Headquarter Mountain View, United States
- Employees 181 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Igm Biosciences, Inc.
-
Annual Revenue
$00as on Jul 07, 2023
-
Net Profit
$-195.8 M21as on Dec 31, 2024
-
EBITDA
$-208.58 M21as on Dec 31, 2024
-
Total Equity Funding
$102.67 M (USD)
in 3 rounds
-
Latest Funding Round
$120 M (USD), Post-IPO
Jul 03, 2023
-
Investors
Haldor Topsoe
& 4 more
-
Employee Count
181
as on Dec 31, 2022
-
Acquired by
Concentra Biosciences
(Jul 01, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of IGM Biosciences
IGM Biosciences offers a comprehensive portfolio of products and services, including IgM Antibodies and Antibody Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Engineered for targeting autoimmune and inflammatory diseases effectively.
Platform for developing IgM-based therapeutics for disease treatment.
Unlock access to complete
Funding Insights of IGM Biosciences
IGM Biosciences has successfully raised a total of $102.67M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $120 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Post-IPO — $120.0M
-
First Round
First Round
(08 Sep 2011)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2023 | Amount | Post-IPO - IGM Biosciences | Valuation |
investors |
|
| Jul, 2019 | Amount | Series C - IGM Biosciences | Valuation | Redmile Group , Janus Henderson Investors | |
| Sep, 2011 | Amount | Seed - IGM Biosciences | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in IGM Biosciences
IGM Biosciences has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Haldor Topsoe, Janus Henderson Investors and Redmile Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Venture capital and private equity firm
|
Founded Year | Domain | Location | |
|
Operates as an employee-owned hedge fund focused on long/short equity strategies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by IGM Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - IGM Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Igm Biosciences Comparisons
Competitors of IGM Biosciences
IGM Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Horizon Therapeutics, Forge Biologics, Dren Bio and argenx, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies are developed for cancer, autoimmune, and serious diseases.
|
|
| domain | founded_year | HQ Location |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Igm Biosciences
Frequently Asked Questions about IGM Biosciences
When was IGM Biosciences founded?
IGM Biosciences was founded in 2010 and raised its 1st funding round 1 year after it was founded.
Where is IGM Biosciences located?
IGM Biosciences is headquartered in Mountain View, United States. It is registered at Mountain View, California, United States.
Who is the current CEO of IGM Biosciences?
Fred M Schwarzer is the current CEO of IGM Biosciences.
Is IGM Biosciences a funded company?
IGM Biosciences is a funded company, having raised a total of $102.67M across 3 funding rounds to date. The company's 1st funding round was a Seed of $671.42K, raised on Sep 08, 2011.
How many employees does IGM Biosciences have?
As of Dec 31, 2022, the latest employee count at IGM Biosciences is 181.
What does IGM Biosciences do?
IGM Biosciences was founded in 2010 in Mountain View, United States, within the biotechnology sector. Focus is placed on developing IgM and IgA antibodies that target CD20, PD-L1, CTLA-4, and death receptor 5. These antibodies are advanced for treating Non-Hodgkins lymphoma, solid tumors, HIV, and HBV. Operations emphasize immune checkpoint modulation and infectious disease control through clinical-stage programs.
Who are the top competitors of IGM Biosciences?
IGM Biosciences's top competitors include Moderna, argenx and Forge Biologics.
What products or services does IGM Biosciences offer?
IGM Biosciences offers IgM Antibodies and Antibody Platform.
Who are IGM Biosciences's investors?
IGM Biosciences has 5 investors. Key investors include Haldor Topsoe, Janus Henderson Investors, Redmile Group, Vivo Capital, and Concentra Biosciences.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.